Onconetix Inc (ONCO) Stock Analysis
Verdict: AVOID
Investment score: 12/100
Analysis as of
Is Onconetix Inc stock worth reviewing? The TradeMates thesis
Onconetix is a distressed biotech with a collapsing share price, dwindling cash, and no Path to profitability. It faces imminent delisting and insolvency risks.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 2/100 (weight 15%)
- Earnings Quality: 10/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 0/100 (weight 10%)
- Risk-Adjusted Return: 5/100 (weight 15%)
Onconetix Inc opportunities and risks
What speaks for ONCO
- FDA Approved Asset (Entadfi)
What speaks against ONCO
- Delisting and Reverse Split Risk
Peers and competitors
- BIEI
- WINT
- BPTH
- SRNE
- NSTM
Frequently asked questions about Onconetix Inc (ONCO)
Is ONCO stock a good investment?
The TradeMates model rates Onconetix Inc as AVOID with an investment score of 12/100. Onconetix is a distressed biotech with a collapsing share price, dwindling cash, and no Path to profitability. It faces imminent delisting and insolvency risks. This is algorithmic model output, not personal investment advice.
Is ONCO stock a buy?
The TradeMates model verdict for ONCO is AVOID with an investment score of 12/100. Treat this as a model signal to review, not a personal buy recommendation.